Shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $3.76 and last traded at $3.88, with a volume of 695,330 shares traded. The stock had previously closed at $4.07.

Several brokerages have issued reports on TBRA. HC Wainwright reissued a “buy” rating on shares of Tobira Therapeutics in a research note on Wednesday, May 4th. Leerink Swann reissued a “buy” rating on shares of Tobira Therapeutics in a research note on Monday, May 2nd. Zacks Investment Research raised shares of Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 price objective for the company in a research note on Saturday, April 23rd. Finally, Cantor Fitzgerald downgraded shares of Tobira Therapeutics to a “buy” rating and set a $19.00 price objective for the company. in a research note on Monday, July 25th. Five analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $16.95.

The stock’s market cap is $77.71 million. The stock has a 50-day moving average of $10.32 and a 200-day moving average of $8.56.

Tobira Therapeutics (NASDAQ:TBRA) last released its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.12. On average, equities research analysts anticipate that Tobira Therapeutics Inc. will post ($2.49) EPS for the current fiscal year.

In other Tobira Therapeutics news, major shareholder A/S Novo sold 187,500 shares of the business’s stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $10.37, for a total transaction of $1,944,375.00. Following the completion of the sale, the insider now directly owns 2,093,905 shares in the company, valued at $21,713,794.85. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

A hedge fund recently bought a new stake in Tobira Therapeutics stock. Marshall Wace LLP acquired a new stake in Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned approximately 0.57% of Tobira Therapeutics at the end of the most recent quarter.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.